Michael Ira Kenneth Elloian

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA.

Part of AstraZeneca PLC, Alexion Pharma UK Ltd. is a pharmaceutical wholesaler founded in 2006. The company is based in Middlesex, UK.

Part of AstraZeneca PLC, Alexion Pharma France SAS operates as a French biotechnology company. The company is based in Levallois-Perret, France. The CEOs are Celine Khalife, Quoc Thevenet. The company was founded in 2005.